NeOnc Technologies   Report issue

For profit Phase 2
Founded: Woodland Hills CA United States (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2016
NCT02704858
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Neonc Technologies, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

perillyl alcohol (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1